

MK-1775 (AZD1775)

产品编号: D50956

CAS: 955365-80-7

分子式: C₂₇H₃₂N₈O₂

纯度: ≥98%

InChi: InChI=1S/C₂₇H₃₂N₈O₂/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H₂,2-4H₃,11,28,29,31)

InChi Key: BKWJAKQVGHWELA-UHFFFAOYSA-N

Smiles: CN1CCN(CC1)C1C=CC(=CC=1)NC1N=C2C(=CN=1)C(=O)N(CC=C)N2C1C=CC=C(N=1)C(C)(C)O

外观: 固体粉末

作用通路: Wee1

溶解性: DMSO up to 100 mM

保存条件: Store in dry, dark place for one year.

产品介绍: MK-1775 (AZD1775) is a highly potent, selective and orally bioavailable Wee1 kinase inhibitor with IC₅₀ of 5.2 nM. It abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin etc. and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells. At tolerated doses, MK-1775 treatment leads to xenograft tumor growth inhibition or regression. It inhibits Wee1 in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. MK-1775 can regress H3K36me3-deficient tumor xenografts too. Right now MK-1775 is in phase I/II clinical trials for various cancers.

CAS号: 955365-80-7

分子式: C₂₇H₃₂N₈O₂

分子量: 500.61

MDL: MFCD17215200

纯度: ≥99.5% (TLC)

外观: 粉末

溶解性: 溶于DMSO (125 mg/mL)

作用靶点: Wee1;

作用通路: Cell Cycle/DNA Damage;

产品描述: 阿达色替 (Adavosertib) 是一种有效的 Wee1 抑制剂, IC₅₀ 值为 5.2 nM。